Study identifier | ICG136 | ICG144 | NCT03222674 | NCT03631576 |
---|---|---|---|---|
Clinical phase | I | I | I/II | II/III |
Target | CLL-1/CD33 | CLL-1/CD33 | Muc1/CLL-1/CD33/CD38/CD56/CD123 | CD123/CLL-1 |
Generation | Second | Second | Fourth | N/A |
Costimulatory domain | CD28 for CLL-1/4-1BB for CD33 | CD28 for CLL-1/4-1BB for CD33 | N/A | N/A |
Transduction method | Lentivirus | Lentivirus | N/A | N/A |
Patient number | 1 | 1 | 10 | 20 |
Age (years) | 44 | 6 | 2–75 | ≦75 |
Conditioning chemotherapy | FC | FC | N/A | N/A |
CAR-T dose | 7 × 105/kg | 1 × 106/kg/days × 2 days | N/A | N/A |
Study start | N/A | N/A | 2017 | 2018 |
Estimated completion date | N/A | N/A | 2020 | 2021 |
Status | N/A | N/A | Recruiting | Recruiting |
Results | MRD− followed by sibling matched HSCT | complete response, followed by Haplo-HSCT | N/A | N/A |
Adverse events | Grade 1 CRS, pancytopenia | Grade 1 CRS, grade 3 neurotoxicity, pancytopenia | N/A | N/A |